Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

Leukemia(2021)10.1038/s41375-021-01328-9Source: DataRank Database

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms is a research paper published in Leukemia (2021). On theSindex it has a DataRank of 0.783. It has been cited 184 times.

N/A

0.783DataRank · unranked

Scored on demand from live citation data

Open Access184 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: hybridTopics (52)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.783

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (40)

Martin Wermke ORCID,Virginia M. Klimek,Peter L. Greenberg ORCID,Patricia Font ORCID,Rami S. Komrokji ORCID

Live enrichment

PubMed:34172893 PMC:PMC8632688

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: P50 CA206963

National Institutes of Health

Grant: 7P50CA206963-03

SPORE in Myeloid Malignancies

H3 Biomedicine Inc

hybridLicense: cc-by

publisherhttps://www.nature.com/articles/s41375-021-01328-9.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8632688

repositoryhttps://escholarship.org/uc/item/20z200m2

Europe_PMChttps://europepmc.org/articles/PMC8632688

Europe_PMChttps://europepmc.org/articles/PMC8632688?pdf=render

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

HumansMyelodysplastic SyndromesPiperazinesPyridinesPhosphoproteinsTreatment OutcomeAdministration, OralDose-Response Relationship, DrugMutation, MissenseAgedAged, 80 and overMiddle AgedFemaleMaleLeukemia, Myeloid, AcutePatient SafetyBiomarkers, TumorRNA Splicing Factors

Keywords

OralMyeloidMalePyridinesMutation, MissenseAdministration, OralAcuteArticlePiperazinesDose-Response Relationship80 and overBiomarkers, TumorHumansAgedAged, 80 and overTumorLeukemiaDose-Response Relationship, DrugMiddle AgedPhosphoproteinsLeukemia, Myeloid, AcuteTreatment OutcomeMyelodysplastic SyndromesAdministrationMutationFemalePatient SafetyRNA Splicing FactorsDrugMissenseBiomarkers

Sustainable Development Goals

SDG 3: 3. Good health